AAAAAA
Results: 1-25/40
Authors:
Harris, KA
Small, EJ
Citation: Ka. Harris et Ej. Small, Hormonal treatment for prostate cancer, EXPERT OP I, 10(3), 2001, pp. 493-510
Authors:
Reese, DM
Small, EJ
Magrane, G
Waldman, FM
Chew, K
Sudilovsky, D
Citation: Dm. Reese et al., HER2 protein expression and gene amplification in androgen-independent prostate cancer, AM J CLIN P, 116(2), 2001, pp. 234-239
Authors:
Small, EJ
Harris, KA
Frohlich, MW
Bok, R
Citation: Ej. Small et al., The UCSF advanced prostate cancer program, UROL ONCOL, 6(5), 2001, pp. 197-201
Authors:
George, DJ
Halabi, S
Shepard, TF
Vogelzang, NJ
Hayes, DF
Small, EJ
Kantoff, PW
Citation: Dj. George et al., Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer andleukemia group B 9480, CLIN CANC R, 7(7), 2001, pp. 1932-1936
Authors:
Ko, YJ
Small, EJ
Kabbinavar, F
Chachoua, A
Taneja, S
Reese, D
DePaoli, A
Hannah, A
Balk, SP
Bubley, GJ
Citation: Yj. Ko et al., A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer, CLIN CANC R, 7(4), 2001, pp. 800-805
Authors:
Mehta, R
Kyshtoobayeva, A
Kurosaki, T
Small, EJ
Kim, H
Stroup, R
McLaren, CE
Li, KT
Fruehauf, JP
Citation: R. Mehta et al., Independent association of angiogenesis index with outcome in prostate cancer, CLIN CANC R, 7(1), 2001, pp. 81-88
Authors:
Rini, BI
Small, EJ
Citation: Bi. Rini et Ej. Small, An update on prostate cancer, CURR OPIN O, 13(3), 2001, pp. 204-211
Authors:
Small, EJ
Citation: Ej. Small, Docetaxel in prostate cancer, ANTI-CANC D, 12, 2001, pp. S17-S20
Authors:
Savarese, DM
Halabi, S
Hars, V
Akerley, WL
Taplin, ME
Godley, PA
Hussain, A
Small, EJ
Vogelzang, NJ
Citation: Dm. Savarese et al., Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780, J CL ONCOL, 19(9), 2001, pp. 2509-2516
Authors:
Small, EJ
McMillan, A
Meyer, M
Chen, L
Slichenmyer, WJ
Lenehan, PF
Eisenberger, M
Citation: Ej. Small et al., Serum prostate-specific antigen decline as a marker of clinical outcome inhormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival, J CL ONCOL, 19(5), 2001, pp. 1304-1311
Authors:
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
Citation: Pw. Kantoff et al., Prognostic significance of reverse transcriptase polymerase chain reactionfor prostate-specific antigen in men with hormone-refractory prostate cancer, J CL ONCOL, 19(12), 2001, pp. 3025-3028
Authors:
Kelly, WK
Curley, T
Slovin, S
Heller, G
McCaffrey, J
Bajorin, D
Ciolino, A
Regan, K
Schwartz, M
Kantoff, P
George, D
Oh, W
Smith, M
Kaufman, D
Small, EJ
Schwartz, L
Larson, S
Tong, W
Scher, H
Citation: Wk. Kelly et al., Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer, J CL ONCOL, 19(1), 2001, pp. 44-53
Authors:
Small, EJ
Bok, R
Reese, DM
Sudilovsky, D
Frohlich, M
Citation: Ej. Small et al., Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer, SEMIN ONCOL, 28(4), 2001, pp. 71-76
Authors:
Grossfeld, GD
Small, EJ
Lubeck, DP
Latini, D
Broering, JM
Carroll, PR
Citation: Gd. Grossfeld et al., Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy, UROLOGY, 58(2A), 2001, pp. 56-64
Authors:
Grossfeld, GD
Chaudhary, UB
Reese, DM
Carroll, PR
Small, EJ
Citation: Gd. Grossfeld et al., Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer, UROLOGY, 58(2), 2001, pp. 240-245
Authors:
Bok, RA
Halabi, S
Fei, DT
Rodriquez, CR
Hayes, DF
Vogelzang, NJ
Kantoff, P
Shuman, MA
Small, EJ
Citation: Ra. Bok et al., Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study, CANCER RES, 61(6), 2001, pp. 2533-2536
Authors:
Small, EJ
Reese, DM
Citation: Ej. Small et Dm. Reese, An update on prostate cancer research, CURR OPIN O, 12(3), 2000, pp. 265-272
Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed
Authors:
Small, EJ
Citation: Ej. Small, Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed, ONCOLOGY-NY, 14(12), 2000, pp. 1692-1693
Authors:
Small, EJ
Meyer, M
Marshall, ME
Reyno, LM
Meyers, FJ
Natale, RB
Lenehan, PF
Chen, L
Slichenmyer, WJ
Eisenberger, M
Citation: Ej. Small et al., Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone, J CL ONCOL, 18(7), 2000, pp. 1440-1450
Authors:
Hussain, M
Fisher, EI
Petrylak, DP
O'Connor, J
Wood, DP
Small, EJ
Eisenberger, MA
Crawford, ED
Citation: M. Hussain et al., Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study, J CL ONCOL, 18(5), 2000, pp. 1043-1049
Authors:
Small, EJ
Fratesi, P
Reese, DM
Strang, G
Laus, R
Peshwa, MV
Valone, FH
Citation: Ej. Small et al., Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells, J CL ONCOL, 18(23), 2000, pp. 3894-3903
Authors:
Small, EJ
Frohlich, MW
Bok, R
Shinohara, K
Grossfeld, G
Rozenblat, Z
Kelly, WK
Corry, M
Reese, DM
Citation: Ej. Small et al., Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer, J CL ONCOL, 18(21), 2000, pp. 3595-3603
Authors:
Roach, M
Reese, D
Weinberg, V
Small, EJ
Carroll, PR
Citation: M. Roach et al., Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?, J CL ONCOL, 18(2), 2000, pp. 448-449
Authors:
Small, EJ
Lew, D
Redman, BG
Petrylak, DP
Hammond, N
Gross, HM
Eastham, JA
Crawford, ED
Citation: Ej. Small et al., Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trialend point, J CL ONCOL, 18(13), 2000, pp. 2537-2544
Authors:
Small, EJ
Figlin, R
Petrylak, D
Vaughn, DJ
Sartor, O
Horak, I
Pincus, R
Kremer, A
Bowden, C
Citation: Ej. Small et al., A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma, INV NEW DR, 18(2), 2000, pp. 193-197